Wolverine Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-45,500
| Closed | -$426K | – | 5630 |
|
|
2025
Q2 | $426K | Buy |
45,500
+2,200
| +5% | +$20.5K | ﹤0.01% | 3115 |
|
|
2025
Q1 | $340K | Sell |
43,300
-11,000
| -20% | -$88.7K | ﹤0.01% | 3385 |
|
|
2024
Q4 | $409K | Buy |
54,300
+13,700
| +34% | +$104K | ﹤0.01% | 3636 |
|
|
2024
Q3 | $309K | Sell |
40,600
-5,700
| -12% | -$43.3K | ﹤0.01% | 3586 |
|
|
2024
Q2 | $286K | Buy |
46,300
+22,100
| +91% | +$122K | ﹤0.01% | 3454 |
|
|
2024
Q1 | $123K | Sell |
24,200
-216,600
| -90% | -$1.22M | ﹤0.01% | 3974 |
|
|
2023
Q4 | $1.44M | Buy |
240,800
+76,100
| +46% | +$441K | ﹤0.01% | 1947 |
|
|
2023
Q3 | $1.17M | Buy |
164,700
+74,700
| +83% | +$537K | ﹤0.01% | 2002 |
|
|
2023
Q2 | $626K | Sell |
90,000
-12,700
| -12% | -$102K | ﹤0.01% | 2397 |
|
|
2023
Q1 | $862K | Buy |
+102,700
| New | +$989K | ﹤0.01% | 2031 |
|
|
2022
Q4 | – | Sell |
-205,600
| Closed | -$2.54M | – | 3981 |
|
|
2022
Q3 | $2.54M | Buy |
205,600
+50,900
| +33% | +$655K | ﹤0.01% | 1237 |
|
|
2022
Q2 | $1.67M | Sell |
154,700
-36,200
| -19% | -$373K | ﹤0.01% | 1520 |
|
|
2022
Q1 | $3.14M | Buy |
+190,900
| New | +$3.06M | ﹤0.01% | 1390 |
|
|
2021
Q4 | – | Sell |
-239,900
| Closed | -$3.45M | – | 5834 |
|
|
2021
Q3 | $3.45M | Buy |
239,900
+89,700
| +60% | +$1.41M | ﹤0.01% | 1599 |
|
|
2021
Q2 | $2.33M | Buy |
150,200
+89,300
| +147% | +$1.21M | ﹤0.01% | 1828 |
|
|
2021
Q1 | $608K | Sell |
60,900
-7,000
| -10% | -$72.2K | ﹤0.01% | 3437 |
|
|
2020
Q4 | $509K | Buy |
67,900
+49,100
| +261% | +$253K | ﹤0.01% | 3148 |
|
|
2020
Q3 | $72K | Sell |
18,800
-24,300
| -56% | -$104K | ﹤0.01% | 4204 |
|
|
2020
Q2 | $215K | Sell |
43,100
-16,900
| -28% | -$67.5K | ﹤0.01% | 3742 |
|
|
2020
Q1 | $119K | Buy |
60,000
+15,000
| +33% | +$41.3K | ﹤0.01% | 3944 |
|
|
2019
Q4 | $145K | Buy |
45,000
+17,300
| +62% | +$43.5K | ﹤0.01% | 4167 |
|
|
2019
Q3 | $88K | Buy |
27,700
+5,200
| +23% | +$16.2K | ﹤0.01% | 3890 |
|
|
2019
Q2 | $85K | Buy |
+22,500
| New | +$135K | ﹤0.01% | 4064 |
|
|
2019
Q1 | – | Sell |
-18,700
| Closed | -$147K | – | 4522 |
|
|
2018
Q4 | $147K | Sell |
18,700
-8,600
| -32% | -$66.9K | ﹤0.01% | 3833 |
|
|
2018
Q3 | $208K | Buy |
+27,300
| New | +$183K | ﹤0.01% | 4219 |
|
|
2017
Q4 | – | Sell |
-45,200
| Closed | -$237K | – | 4895 |
|
|
2017
Q3 | $237K | Buy |
+45,200
| New | +$231K | ﹤0.01% | 3592 |
|
|
2017
Q2 | – | Sell |
-46,200
| Closed | -$384K | – | 4263 |
|
|
2017
Q1 | $384K | Sell |
46,200
-124,200
| -73% | -$864K | ﹤0.01% | 2708 |
|
|
2016
Q4 | $1.08M | Buy |
170,400
+96,800
| +132% | +$504K | 0.01% | 1843 |
|
|
2016
Q3 | $328K | Buy |
+73,600
| New | +$294K | ﹤0.01% | 3106 |
|
Other funds holding BCRX
DM
KCM
Wolverine Trading's BCRX Position: Q3 2024 in Review
Wolverine Trading sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 10,609 shares — an estimated $80.6K sold.
Wolverine Trading first reported a position in BCRX in Q3 2016 and held it in 19 quarters. The position peaked at $1.03M in Q2 2021. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.
- Wolverine Trading reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
- Wolverine Trading sold 10,609 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $80.6K.
- Wolverine Trading first reported a position in BioCryst Pharmaceuticals in Q3 2016 and held it in 19 quarters.
- Wolverine Trading's BioCryst Pharmaceuticals position peaked at $1.03M in Q2 2021.
- 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.
Based on Wolverine Trading's 13F filing for Q3 2024, filed 14 Nov 2024.